SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001274644-15-000052
Filing Date
2015-09-16
Accepted
2015-09-16 16:06:50
Documents
3
Period of Report
2015-09-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K OCERA INITIATES PHASE 1 CLINICAL TRIAL OF ORAL DRUG CANDIDATE ocera-form8xkclinicalupdat.htm 8-K 26019
2 EXHIBIT 99.1 OCERA INITIATES PHASE 1 CLINICAL TRIAL ocerainitiatesphase1clinic.htm EX-99.1 13766
3 ocerainitiatesphase1c_image1.jpg GRAPHIC 23227
  Complete submission text file 0001274644-15-000052.txt   73003
Mailing Address 525 UNIVERSITY AVENUE SUITE 610 PALO ALTO CA 94301
Business Address 525 UNIVERSITY AVENUE SUITE 610 PALO ALTO CA 94301 6504625800
Ocera Therapeutics, Inc. (Filer) CIK: 0001274644 (see all company filings)

IRS No.: 631192270 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35119 | Film No.: 151110397
SIC: 2834 Pharmaceutical Preparations